塩化ツボクラリン

関: d-tubocurarine、tubocurarine

WordNet

any compound containing a chlorine atom
any salt of hydrochloric acid (containing the chloride ion)
a toxic alkaloid found in certain tropical South American trees that is a powerful relaxant for striated muscles; "curare acts by blocking cholinergic transmission at the myoneural junction" (同)curare

PrepTutorEJDIC

塩化物

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/07/03 09:08:07」(JST)

wiki en

[Wiki en表示]

Tubocurarine (also known as D-tubocurarine or DTC) is a skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to provide skeletal muscle relaxation during surgery or mechanical ventilation. Unlike a number of other related skeletal muscle relaxants, it is now rarely considered clinically to facilitate endotracheal intubation.

Tubocurarine is classified as a long-duration,^[1] antagonist for Nicotinic acetylcholine receptor.^[2] It is the active agent of curare.

Currently, tubocurarine is rarely used as an adjunct for clinical anesthesia because safer alternatives, such as cisatracurium and rocuronium, are available.

History[edit]

Tubocurare is a naturally occurring mono-quaternary alkaloid obtained from the bark of the South American plant Chondrodendron tomentosum, a climbing vine known to the European world since the Spanish conquest of South America. Curare had been used as a source of arrow poison by South American natives to hunt animals, and they were able to eat the animals' contaminated flesh subsequently without any untoward effects, because tubocurarine cannot easily cross mucous membranes. Tubocurarine is thus effective only if given parenterally, as demonstrated by Bernard, who also showed the site of its action was at the neuromuscular junction.^[3] Virchow and Munter confirmed the paralyzing action was limited to voluntary and not involuntary muscles.^[4] Thus, a conscious individual administered this agent will be unable to move any voluntary muscles, including the diaphragm: a large enough dose will therefore result in death from respiratory failure unless artificial ventilation is initiated.

The word "curare" comes from the South American Indian name for the arrow poison, ourare. Presumably, the initial syllable was pronounced with a heavy glottal stroke. Tubocurarine is so-called because the plant samples containing the curare were stored and shipped to Europe in tubes. Likewise, curare stored in calabash containers was called calabash curare.

Structurally, tubocurarine is a benzylisoquinoline derivative. For many years, its structure, when first elucidated in 1948,^[5] was wrongly thought to be bis-quaternary: in other words, it was thought to be an N,N-dimethylated alkaloid. In 1970, the correct structure was finally established,^[6] showing one of the two nitrogens to be tertiary, actually a mono-N-methylated alkaloid.

Griffith and Johnson are credited with pioneering the formal clinical introduction of tubocurarine as an adjunct to anesthetic practice on 23 January 1942, at the Montreal Homeopathic Hospital.^[7] In this sense, tubocurarine is the prototypical adjunctive neuromuscular blocking agent. However, others before Griffith and Johnson had attempted use of tubocurare in several situations:^[8]^[9]^[10] some under controlled study conditions^[11]^[12] while others not quite controlled and remained unpublished.^[13] Regardless, all in all some ~30,000 patients had been given tubocurare by 1941, although it was Griffith and Johnson's 1942 publication^[7] that provided the impetus to the standard use of neuromuscular blocking agents in clinical anesthestic practice - a revolution that rapidly metamorphosized into the standard practice of "balanced" anesthesia: the triad of barbiturate hypnosis, light inhalational anesthesia and muscle relaxation.^[14] The technique as described by Gray and Halton was widely known as the "Liverpool technique",^[14] and became the standard anesthetic technique in England in the 1950s and 1960s for patients of all ages and physical status. Present clinical anesthetic practice still employs the central principle of balanced anesthesia though with some differences to accommodate subsequent technological advances and introductions of new and better gaseous anesthetic, hypnotic and neuromuscular blocking agents, and tracheal intubation, as well as monitoring techniques that were nonexistent in the day of Gray and Halton: pulse oximetry, capnography, peripheral nerve stimulation, noninvasive blood pressure monitoring, etc.

Biosynthesis[edit]

Tubocurarine biosynthesis involves a radical coupling of two enantiomeric tetrahydrobenzylisoquinolines, more specifically, the two enantiomers of N-methyl-coclaurine. (R) and (S)-N-methyl-coclaurine come from a Mannich-like reaction between dopamine and 4-hydroxyphenyl-acetaldehyde, facilitated by norcoclaurine synthase (NCS). Both dopamine and 4-hydroxyphenylacetyladehyde originate from L-tyrosine. The biosynthetic pathway is described in more detail in the figures. Methylation of the amine and hydroxyl substituents are facilitated by S-adenosyl methionine (SAM).^[15]

Clinical pharmacology and pharmacokinetics[edit]

Tubocurarine has a time of onset of 300 seconds or more (which is relatively slow among neuromuscular-blocking drugs), and has a duration of action of 60 to 120 minutes (which is relatively long time).^[16]

It also causes histamine release,^[17] now a recognized hallmark of the tetrahydroisioquinolinium class of neuromuscular blocking agents. The amount of histamine release in some instances following tubocurarine administration is such that it is contraindicated in asthmatics and patients with allergies.^{[citation needed]} However, the main disadvantage in the use of tubocurarine is its significant ganglion-blocking effect,^[18] that manifests as hypotension,^[19] in many patients; this constitutes a relative contraindication to its use in patients with myocardial ischaemia.

Because of the shortcomings of tubocurare, much research effort was undertaken soon after its clinical introduction to find a suitable replacement. The efforts unleashed a multitude of compounds borne from structure-activity relations developed from the tubocurare molecule. Some key compounds that have seen clinical use are identified in the muscle relaxants template box below. Of the many tried as replacements, only a few enjoyed as much popularity as tubocurarine: pancuronium, vecuronium, rocuronium, atracurium, and cisatracurium. Succinylcholine is a widely used paralytic drug which acts by activating, instead of blocking, the ACh receptor.

The potassium channel blocker tetraethylammonium (TEA) has been shown to reverse the effects of tubocurarine. It is thought to do so by increasing ACh release, which counteracts the antagonistic effects of tubocurarine on the ACh receptor.

References[edit]

^ Thompson MA (1980). "Muscle relaxant drugs". Br J Hosp Med 23 (2): 153–4, 163–4, 167–8 passim. PMID 6102875.
^ Wenningmann I, Dilger JP (October 2001). "The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium". Molecular Pharmacology 60 (4): 790–6. PMID 11562442.
^ Bernard C (1856). "Analyse physiologie des propriétés des actions de curare et de la nicotine sure systèmes musculaire et nerveux au moyen du curare". Compt. Rend. 43: 305–319.
^ Bechter AM (1977). "The civilizing of curare: a history of its development and introduction into anesthesiology". Anesth Analg 56 (2): 305–319. PMID 322548.
^ King H (1948). "64. Curare alkaloids. Part VII. Constitution of dextrotubocurarine chloride". J Chem Soc: 265. doi:10.1039/jr9480000265.
^ Everett AJ, Lowe LA, Wilkinson S (1970). J Chem Soc, Chem Commun: 1020.
^ ^a ^b Griffith HR, Johnson GE (1942). "The use of curare in general anesthesia". Anesthesiol 3 (4): 418–420. doi:10.1097/00000542-194207000-00006.
^ Läwen A (1912). "Ueber die verbindung der lokakanaesthesie und epidurale injektion anesthesiernder losungen bei tabischen magenkrisen". Beitr Klin Chir 80: 168–189.
^ Wilkinson DJ (1991). "Dr. F.P. de Caux - the first user of curare for anaesthesia in England". Anaesthesia 46 (1): 49–51. doi:10.1111/j.1365-2044.1991.tb09317.x. PMID 1996757.
^ Bennett AE (1941). "Curare: a preventive of traumatic complications in electroconvulsive shock therapy". Am J Psychiatry 97: 1040–1060.
^ West R (1984). "An excursion into pharmacology: curare in medicine". Medical History 28 (4): 391–405. PMC 1140012. PMID 6390032.
^ Burman MS (1939). "Therapeutic use of curare and erythroidine hydrochloride for spastic and dystonic states". Arch Neurol Psychiat 41: 307–327.
^ Bevan DR. (1992) "Curare". In: Maltby JR, Shephard DAE (Eds.), Harold Griffith - His Life and Legacy; Suppl. to Can J Anaesth Vol. 39 (1); 49-55.
^ ^a ^b Gray TC, Halton J (1946). "Technique for the use of d-tubocurarine chloride with balanced anaesthesia". Br Med J 2: 293–295. PMID 20996123.
^ Dewick, P. M. Medicinal Natural Products; a Biosynthetic Approach. 3rd ed.; John Wiley and Sons Ltd.: 2009.
^ Page 151 in: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. OCLC 51622037.
^ Maclagen J. (1976) In: Zaimis E. (Ed.), "Neuromuscular Junction". Hand. Exp. Pharm.; Vol. 42; Springer-Verlag, Berlin: 421-486.
^ Bowman WC, Webb SN (1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat". J Pharm Pharmacol 24 (10): 762–72. PMID 4403972.
^ Coleman AJ, Downing JW, Leary WP, Moyes DG (1972). "The immediate cardiovascular effects of pancuronium, alcuronium and tubocurarine in man". Anaesthesia 27 (4): 415–22. doi:10.1111/j.1365-2044.1972.tb08247.x. PMID 4264060.

External links[edit]

Curare - History, Tubocurarine, a more detailed historical account of tubocurare

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 重症患者における神経筋遮断剤の使用 use of neuromuscular blocking medications in critically ill patients
2. 周術期アナフィラキシー：再発反応の評価および予防 perioperative anaphylaxis evaluation and prevention of recurrent reactions
3. Perioperative anaphylaxis: Clinical manifestations, etiology, and management
4. 肥満細胞：表面受容体とシグナル伝達 mast cells surface receptors and signal transduction
5. 術後肺合併症のマネージメントの概要 overview of the management of postoperative pulmonary complications

English Journal

Nicotine promotes rooting in leaf explants of in vitro raised seedlings of tomato, Lycopersicon esculentum Miller var. Pusa Ruby.

Bamel K1, Gupta R2, Gupta SC2.
International immunopharmacology.Int Immunopharmacol.2015 Sep 9. pii: S1567-5769(15)30104-1. doi: 10.1016/j.intimp.2015.09.001. [Epub ahead of print]
Nicotine promotes rooting in leaf explants of tomato (Lycopersicon esculentum Miller var. Pusa Ruby). Nicotine at 10-9 to 10-3M concentrations was added to the MS basal medium. The optimum response (three-fold increase in rooting) was obtained at 10-7M nicotine-enriched MS medium. At the same level
PMID 26363975

Oseltamivir produces hypothermic and neuromuscular effects by inhibition of nicotinic acetylcholine receptor functions: Comparison to procaine and bupropion.

Fukushima A1, Chazono K2, Hashimoto Y2, Iwajima Y2, Yamamoto S2, Maeda Y3, Ohsawa M2, Ono H4.
European journal of pharmacology.Eur J Pharmacol.2015 Sep 5;762:275-82. doi: 10.1016/j.ejphar.2015.06.004. Epub 2015 Jun 3.
Oseltamivir, an anti-influenza virus drug, induces marked hypothermia in normal mice. We have proposed that the hypothermic effect arises from inhibition of the nicotinic acetylcholine receptor function of sympathetic ganglion neurons which innervate the brown adipose tissue (a heat generator). It h
PMID 26049014

A single polycystic kidney disease 2-like 1 channel opening acts as a spike generator in cerebrospinal fluid-contacting neurons of adult mouse brainstem.

Orts Del'Immagine A1, Seddik R1, Tell F2, Airault C1, Er-Raoui G3, Najimi M4, Trouslard J5, Wanaverbecq N6.
Neuropharmacology.Neuropharmacology.2015 Jul 25. pii: S0028-3908(15)30037-X. doi: 10.1016/j.neuropharm.2015.07.030. [Epub ahead of print]
Cerebrospinal fluid contacting neurons (CSF-cNs) are found around the central canal of all vertebrates. They present a typical morphology, with a single dendrite that projects into the cavity and ends in the CSF with a protuberance. These anatomical features have led to the suggestion that CSF-cNs m
PMID 26220314

Japanese Journal

コイの脳血流と心拍に及ぼす急性低酸素の影響

松井春樹,吉川弘正,中村聡一 [他],川合文雄,金森正雄,小林博,中村聡一,ナカムラソウイチ,Nakamura Soichi,河合文雄,カワイフミオ,Kawai Fumio,金森正雄,カナモリマサオ,Kanamori Masao,小林博,コバヤシヒロシ,Kobayashi Hiroshi
近畿大学農学部紀要 29, 39-51, 1996-03-15
低酸素時における脳血流量と心拍数を筋弛緩剤(d-塩化ツボクラリン4mg/kg)で不動化した体重約500gのコイを用いて水温23±1℃のもとで測定した。脳血流量は終脳表面でレーザードップラー組織血流計により計測した。軽度の低酸素下(呼吸水の酸素分圧が100と75mmHg)では,脳血流量も心拍数も実験開始時(通常状態)と変わらず一定であった。酸素分圧が25mmHg以下では脳血流量は通常状態に比べて有意 …
NAID 110000978641

Application of 10.6μm CO_2 Laser to the Electrospray and Ion Spray LC/MS Interface

Hiraoka Kenzo [他],KATAYAMA Shinsuke,AIZAWA Keiichi,MATSUSHITA Fumiko,FUKASAWA Hiroko
質量分析 = Mass spectroscopy 43(5), 265-277, 1995-10-30
… When IR laser was irradiated on the electrosprayed charged liquid droplets for 10-5 M tubocurarine chloride (M) solution in isopropanol/aqueous NH3 (29%) solution, the intensity of the singly charged ion (M-HCl-Cl)+ increased but that of doubly charged ion (M-2Cl)2+ decreased. …
NAID 10016279012

An acetylcholine-induced potassium current in tail sensory neurons in the pleural ganglion of Aplysia.

ICHINOSE Mitsuyuki,SAWADA Masashi,MAENO Takashi
The Japanese Journal of Physiology 38(4), 563-568, 1988
… the cholinergic antagonists, d-tubocurarine chloride (d-TC), and atropine mildly reduced the ACh response, while tetraethylammonium (TEA) most effectively blocked this response. …
NAID 130003477337

「ツボクラリン」

Tubocurarine chloride
Systematic (IUPAC) name
	6,6'-dimethoxy-2,2,2',2'-tetramethyltubocuraran-2,2'-diium-7',12'-diol
Clinical data
AHFS/Drugs.com	International Drug Names
MedlinePlus	a682860
Pregnancy cat.	D
Legal status	World wide Rx-only medication
Routes	IV
Pharmacokinetic data
Bioavailability	100% (IV)
Protein binding	50%
Half-life	1-2 hours
Identifiers
CAS number	57-95-4 (chloride hydrochloride); 6989-98-6 (chloride hydrochloride pentahydrate)
ATC code	M03AA02
PubChem	CID 6000
DrugBank	DB01199
ChemSpider	5778
UNII	900961Z8VR
ChEBI	CHEBI:9774
ChEMBL	CHEMBL1687
Chemical data
Formula	C37H42Cl2N2O6
Mol. mass	624.765 g/mol
	SMILES Oc7ccc1cc7Oc5cc6[C@H](Cc4ccc(Oc2c3[C@@H](C1)[N+](C)(C)CCc3cc(OC)c2O)cc4)[N+](C)(C)CCc6cc5OC;
	InChI InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-37-35-25(20-34(43-5)36(37)41)13-15-39(2,3)29(35)17-23-8-11-30(40)31(18-23)45-33/h6-11,18-21,28-29H,12-17H2,1-5H3,(H-,40,41)/p+1/t28-,29+/m0/s1 ; Key:JFJZZMVDLULRGK-URLMMPGGSA-O ;
(what is this?) (verify);

　　[★]

英: tubocurarine、tubocurarine chloride
関: d-ツボクラリン、塩化ツボクラリン

「塩化ツボクラリン」

　　[★]

英: tubocurarine chloride
関: ツボクラリン、d-ツボクラリン

「chloride」

　　[★] 塩素イオン　　　

[1] Thompson MA (1980). "Muscle relaxant drugs". Br J Hosp Med 23 (2): 153–4, 163–4, 167–8 passim. PMID 6102875.

[pmid11562442-2] Wenningmann I, Dilger JP (October 2001). "The kinetics of inhibition of nicotinic acetylcholine receptors by (+)-tubocurarine and pancuronium". Molecular Pharmacology 60 (4): 790–6. PMID 11562442.

[3] Bernard C (1856). "Analyse physiologie des propriétés des actions de curare et de la nicotine sure systèmes musculaire et nerveux au moyen du curare". Compt. Rend. 43: 305–319.

[4] Bechter AM (1977). "The civilizing of curare: a history of its development and introduction into anesthesiology". Anesth Analg 56 (2): 305–319. PMID 322548.

[5] King H (1948). "64. Curare alkaloids. Part VII. Constitution of dextrotubocurarine chloride". J Chem Soc: 265. doi:10.1039/jr9480000265.

[6] Everett AJ, Lowe LA, Wilkinson S (1970). J Chem Soc, Chem Commun: 1020.

[Griffith-7] Griffith HR, Johnson GE (1942). "The use of curare in general anesthesia". Anesthesiol 3 (4): 418–420. doi:10.1097/00000542-194207000-00006.

[8] Läwen A (1912). "Ueber die verbindung der lokakanaesthesie und epidurale injektion anesthesiernder losungen bei tabischen magenkrisen". Beitr Klin Chir 80: 168–189.

[9] Wilkinson DJ (1991). "Dr. F.P. de Caux - the first user of curare for anaesthesia in England". Anaesthesia 46 (1): 49–51. doi:10.1111/j.1365-2044.1991.tb09317.x. PMID 1996757.

[10] Bennett AE (1941). "Curare: a preventive of traumatic complications in electroconvulsive shock therapy". Am J Psychiatry 97: 1040–1060.

[11] West R (1984). "An excursion into pharmacology: curare in medicine". Medical History 28 (4): 391–405. PMC 1140012. PMID 6390032.

[12] Burman MS (1939). "Therapeutic use of curare and erythroidine hydrochloride for spastic and dystonic states". Arch Neurol Psychiat 41: 307–327.

[13] Bevan DR. (1992) "Curare". In: Maltby JR, Shephard DAE (Eds.), Harold Griffith - His Life and Legacy; Suppl. to Can J Anaesth Vol. 39 (1); 49-55.

[Gray-14] Gray TC, Halton J (1946). "Technique for the use of d-tubocurarine chloride with balanced anaesthesia". Br Med J 2: 293–295. PMID 20996123.

[15] Dewick, P. M. Medicinal Natural Products; a Biosynthetic Approach. 3rd ed.; John Wiley and Sons Ltd.: 2009.

[Rang151-16] Page 151 in: Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. OCLC 51622037.

[17] Maclagen J. (1976) In: Zaimis E. (Ed.), "Neuromuscular Junction". Hand. Exp. Pharm.; Vol. 42; Springer-Verlag, Berlin: 421-486.

[18] Bowman WC, Webb SN (1972). "Neuromuscular blocking and ganglion blocking activities of some acetylcholine antagonists in the cat". J Pharm Pharmacol 24 (10): 762–72. PMID 4403972.

[19] Coleman AJ, Downing JW, Leary WP, Moyes DG (1972). "The immediate cardiovascular effects of pancuronium, alcuronium and tubocurarine in man". Anaesthesia 27 (4): 415–22. doi:10.1111/j.1365-2044.1972.tb08247.x. PMID 4264060.

リンク元	「ツボクラリン」「塩化ツボクラリン」
関連記事	「chloride」

匿名

検索

案内

案内

tubocurarine chloride